Stocktoria
Connect Biopharma Holdings Ltd CNTB
Connect Biopharma Holdings Ltd (CNTB) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $64,000 at a -86687.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
FAQ
Is CNTB financially healthy?
Connect Biopharma Holdings Ltd's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does CNTB pay a dividend?
No, Connect Biopharma Holdings Ltd does not currently pay a dividend.
How profitable is CNTB?
In FY2025, Connect Biopharma Holdings Ltd had a net margin of -86687.5% and a return on equity of -132.2%.
What is the analyst price target for CNTB?
The average Wall-Street price target for Connect Biopharma Holdings Ltd is $7.00, about 200.4% above the recent price, from 7 analysts (consensus: strong buy).
Is CNTB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Connect Biopharma Holdings Ltd: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.